Cabaletta Bio

Contributing Author

Recent Articles by Cabaletta Bio

Nov-10	Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update CABA GlobeNewswire
Nov-04	Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December CABA GlobeNewswire
Oct-27	Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 CABA GlobeNewswire
Oct-14	Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant CABA GlobeNewswire
Oct-09	Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress CABA GlobeNewswire
Aug-27	Cabaletta Bio to Participate in Upcoming Investor Conferences in September CABA GlobeNewswire
Aug-07	Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update CABA GlobeNewswire
Jun-11	Cabaletta Bio Announces Pricing of Public Offering of Securities CABA GlobeNewswire
Jun-11	Cabaletta Bio Announces Proposed Public Offering of Securities CABA GlobeNewswire
Jun-11	Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress CABA GlobeNewswire
May-29	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference CABA GlobeNewswire
May-15	Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts CABA GlobeNewswire